Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The current anti-rejection drug regime for kidney transplant recipients in use at the West
London Renal & Transplant Centre (WLRaTC) consists of induction therapy with the very potent
monoclonal antibody Campath 1-H (Alemtuzumab) followed by long-term maintenance with the
Calcineurin inhibitor Tacrolimus
The recent development (and licensing in the UK) of an extended-release, once daily
formulation of Tacrolimus holds out the promise of simpler drug regimes for our patients. In
the context of our current successful use of Tacrolimus monotherapy maintenance after Campath
1-H induction, the extended-release Tacrolimus formulation will enable us to offer a regime
where the only long-term immunosuppressive treatment that most of our patients need will be a
single drug, taken once a day.
The investigators wish to assess the efficacy of such a regime in a structured comparison
with our current protocol.
Phase:
Phase 4
Details
Lead Sponsor:
Hammersmith Hospitals NHS Trust Imperial College Healthcare NHS Trust